This morning, CVS Caremark (NYSE:CVS) reported second quarter earnings of $1.12 billion, or 91 cents per share, as revenue climbed by 2% to $31.25 billion. The company said that its profit margins have benefited from the increase in generic drugs available, but noted that sales growth could taper as a side effect. In the report, CVS narrowed its full-year earnings forecast to the range of $3.90 to $3.96 per share. In early trading, shares of CVS inched higher, approaching $62 per share and its 52 week high.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.